In a meta-analysis of 17 MDD clinical trials (n=14,779), patients with improvement by Day 14 were:
Remission was defined as a cutoff score ≤7 in the HDRS or ≤12 in the MADRS at the end of treatment.1
Response was defined as a ≥50% reduction in depression severity (HDRS/MADRS) from treatment initiation to discharge.1
*Early improvement was defined as a ≥20%, ≥25%, or ≥30% reduction of depressive severity on scales such as HDRS and MADRS from baseline to Day 14.1
†Meta-analysis of 17 randomized, double-blind, or placebo-controlled studies comparing a monotherapy with an antidepressant drug against placebo or another antidepressant in 14,779 adult patients with acute MDD according to DSM-IV, DSM-III-R, or DSM-III,
published through July 7, 2016.1
DSM-III=Diagnostic and Statistical Manual of Mental Disorders, third edition; DSM-III-R=revised third edition; DSM-IV=fourth edition; HDRS=Hamilton Depression Rating Scale; MADRS=Montgomery–Åsberg Depression Rating Scale; MDD=major depressive disorder.